AstraZeneca’s CEO, Pascal Soriot, has made it clear that he is considering relocating the company’s stock market listing from the UK to the US. This decision, if made, would not just be a corporate maneuver; it would signify a troubling trend of British companies seeking more favorable conditions abroad, ultimately undermining the UK’s financial prestige.
The Times reports that Soriot has a strong preference for New York, a testament to the ongoing exodus of firms from the London Stock Exchange, which has suffered a series of losses as companies like Ashtead and Flutter Entertainment depart for higher valuations. The latest increase in AstraZeneca’s share price—up by 2.8%—follows this news, reflecting a disheartening reality in which British firms find themselves more valued on foreign exchanges.
A relocation of AstraZeneca would strike a major blow to the London Stock Exchange, which is already reeling from numerous elite companies seeking greener pastures. The ongoing drift of our most valuable assets raises serious questions about confidence in the UK’s economic environment. The glaring issue of corporate elitism comes into play, as these companies prioritize shareholder interests over national pride.
The UK government, while expressing concerns, lacks the authority to block such a strategic move. Labour’s emphasis on life sciences as a pivotal growth sector highlights a misguided approach towards nurturing homegrown industries. The government’s failure to create an environment conducive to business growth—a mix of regulatory overreach and harmful tax strategies—further complicates this landscape.
While AstraZeneca has chosen not to comment directly, the underlying tension remains palpable. The government’s ongoing negotiations with pharmaceutical companies over rebates, particularly regarding sales of new medicines to the NHS, demonstrate an outdated approach that risks stifling innovation. Soriot’s frustration over cost-related rejections of drugs like Enhertu underscores a more significant problem within a healthcare system burdened by political decisions.
Earlier this year, AstraZeneca’s decision to withdraw from a substantial £450 million vaccine production project in Liverpool sent shockwaves through government corridors. Their stated reasoning—a lack of financial support from the government—highlights the need for greater fiscal responsibility and sensibility in dealings with businesses. Such instances reveal the pitfalls of a government that favors intervention over collaboration.
Since taking the helm in 2012, Soriot has seen AstraZeneca’s valuation soar—now worth approximately £157 billion, surpassing traditional powerhouses like Shell and HSBC. This impressive growth underlines the inherent potential within the market, yet raises alarms about a UK business environment that fails to retain its champions.
after newsletter promotion
The United States stands as the largest pharmaceutical market globally, characterized by unprecedented spending on medications. Despite a troubling trend of lower life expectancies compared to other nations, UK executives have long complained of being undervalued compared to their American counterparts. This reality demands a reevaluation of policy to foster a supportive environment for our businesses.
Soriot’s commitment to growth in the US market echoes a broader trend: the urgent need for UK firms to assert their importance on the global stage. His statements about the need for growth highlight not only AstraZeneca’s ambitions but also the necessity for sound, pro-business policies that endorse innovation and free-market principles.
It is important to note that Soriot’s rising compensation—a staggering £16.85 million for 2023—reflects the increasing value of AstraZeneca. While some may view this as excessive, it illustrates how performance should correlate with compensation. True personal responsibility and meritocracy should prevail, where hard work and success are duly rewarded.
